Peter Salgo, MD; John L. Fox, MD, MHA; Ira M. Klein, MD, MBA, FACP; Michael Kolodziej, MD; Bryan Loy, MD; and Irwin W. Tischler, DO, highlight projects such as CEO Cancer Life Sciences Consortium’s Project Data Sphere, Yale and Janssen’s Yale School of Medicine’s Open Data Access Project, and the National Institutes of Health’s Big Data To Knowledge initiative, and discuss their roles in integrating data from key cancer trials.
Although the panelists agree that these programs and similar initiatives show great promise in terms of potentially influencing drug development and patient care in oncology, Dr Loy remarks that it remains to be seen whether the programs can collect data and process them into a form that is useful and relevant. Drs Fox and Klein add that financial and privacy barriers may prevent key stakeholders from accessing and using data.
According to Dr Kolodziej, patient demands, or consumerism, may drive the future development of oncology drugs. He explains that patients are now conducting their own research on the Internet before meeting with healthcare professionals. However, Dr Fox questions the level of influence that patients have with regard to drug development, and remarks that pharmaceutical companies determine where to invest their money in terms of research and development.
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More